AstraZeneca CEO David Brennan will retire from his post, ending a six-year tenure after repeated failures in drug development left investors skeptical of the company's earnings prospects.
AstraZeneca's Brennan to retire from CEO post
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.